EGFR and non-small cell lung carcinoma: These findings represent a more favorable OS than observed in previous studies of first-line erlotinib in EGFR mutation-positive NSCLC outside Japan (median OS range 22.9–26.3 months [12, 13, 16]), and are in line with results from prospective studies of other EGFR TKIs in Japanese populations (median OS range 27.7–34.8 months [10, 11]).